CHEMICAL IDENTIFICATION
-
RTECS NUMBER :
-
QJ6475000
-
CHEMICAL NAME :
-
2,7-Naphthalenedisulfonic acid, 3,3'-((3,3'-dimethyl-4,4'-biphenylylene)bis(azo))bis( 5- amino-4-hydroxy-, tetrasodium salt
-
CAS REGISTRY NUMBER :
-
72-57-1
-
LAST UPDATED :
-
199710
-
DATA ITEMS CITED :
-
82
-
MOLECULAR FORMULA :
-
C34-H28-N6-O14-S4.4Na
-
MOLECULAR WEIGHT :
-
964.88
-
WISWESSER LINE NOTATION :
-
L66J BQ DSWQ HSWQ JZ CNUNR B D- 2 &-NA- 4
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
-
TYPE OF TEST :
-
LD50 - Lethal dose, 50 percent kill
-
ROUTE OF EXPOSURE :
-
Oral
-
SPECIES OBSERVED :
-
Rodent - rat
-
DOSE/DURATION :
-
6200 mg/kg
-
TOXIC EFFECTS :
-
Details of toxic effects not reported other than lethal dose value
-
TYPE OF TEST :
-
LDLo - Lowest published lethal dose
-
ROUTE OF EXPOSURE :
-
Intraperitoneal
-
SPECIES OBSERVED :
-
Rodent - rat
-
DOSE/DURATION :
-
300 mg/kg
-
TOXIC EFFECTS :
-
Lungs, Thorax, or Respiration - acute pulmonary edema
-
TYPE OF TEST :
-
LDLo - Lowest published lethal dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
SPECIES OBSERVED :
-
Rodent - rat
-
DOSE/DURATION :
-
300 mg/kg
-
TOXIC EFFECTS :
-
Lungs, Thorax, or Respiration - acute pulmonary edema
-
TYPE OF TEST :
-
LDLo - Lowest published lethal dose
-
ROUTE OF EXPOSURE :
-
Intravenous
-
SPECIES OBSERVED :
-
Rodent - rat
-
DOSE/DURATION :
-
300 mg/kg
-
TOXIC EFFECTS :
-
Lungs, Thorax, or Respiration - acute pulmonary edema
-
TYPE OF TEST :
-
LDLo - Lowest published lethal dose
-
ROUTE OF EXPOSURE :
-
Intraperitoneal
-
SPECIES OBSERVED :
-
Rodent - mouse
-
DOSE/DURATION :
-
350 mg/kg
-
TOXIC EFFECTS :
-
Lungs, Thorax, or Respiration - acute pulmonary edema
-
TYPE OF TEST :
-
LD50 - Lethal dose, 50 percent kill
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
SPECIES OBSERVED :
-
Rodent - mouse
-
DOSE/DURATION :
-
267 mg/kg
-
TOXIC EFFECTS :
-
Details of toxic effects not reported other than lethal dose value
-
TYPE OF TEST :
-
LD50 - Lethal dose, 50 percent kill
-
ROUTE OF EXPOSURE :
-
Intravenous
-
SPECIES OBSERVED :
-
Rodent - mouse
-
DOSE/DURATION :
-
328 mg/kg
-
TOXIC EFFECTS :
-
Details of toxic effects not reported other than lethal dose value
-
TYPE OF TEST :
-
LDLo - Lowest published lethal dose
-
ROUTE OF EXPOSURE :
-
Intraperitoneal
-
SPECIES OBSERVED :
-
Rodent - rabbit
-
DOSE/DURATION :
-
400 mg/kg
-
TOXIC EFFECTS :
-
Lungs, Thorax, or Respiration - acute pulmonary edema
-
TYPE OF TEST :
-
LDLo - Lowest published lethal dose
-
ROUTE OF EXPOSURE :
-
Intravenous
-
SPECIES OBSERVED :
-
Rodent - rabbit
-
DOSE/DURATION :
-
100 mg/kg
-
TOXIC EFFECTS :
-
Lungs, Thorax, or Respiration - acute pulmonary edema
-
TYPE OF TEST :
-
LDLo - Lowest published lethal dose
-
ROUTE OF EXPOSURE :
-
Intraperitoneal
-
SPECIES OBSERVED :
-
Rodent - guinea pig
-
DOSE/DURATION :
-
250 mg/kg
-
TOXIC EFFECTS :
-
Lungs, Thorax, or Respiration - acute pulmonary edema
-
TYPE OF TEST :
-
LDLo - Lowest published lethal dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
SPECIES OBSERVED :
-
Rodent - guinea pig
-
DOSE/DURATION :
-
300 mg/kg
-
TOXIC EFFECTS :
-
Lungs, Thorax, or Respiration - acute pulmonary edema
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
SPECIES OBSERVED :
-
Rodent - rat
-
DOSE/DURATION :
-
630 mg/kg/43W-I
-
TOXIC EFFECTS :
-
Tumorigenic - Carcinogenic by RTECS criteria Tumorigenic - tumors at site of application
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Parenteral
-
SPECIES OBSERVED :
-
Rodent - rat
-
DOSE/DURATION :
-
250 mg/kg/10W-I
-
TOXIC EFFECTS :
-
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Blood - lymphoma, including Hodgkin's disease
-
TYPE OF TEST :
-
TD - Toxic dose (other than lowest)
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
SPECIES OBSERVED :
-
Rodent - rat
-
DOSE/DURATION :
-
7500 mg/kg/86W-I
-
TOXIC EFFECTS :
-
Tumorigenic - neoplastic by RTECS criteria Liver - tumors Tumorigenic - tumors at site of application
-
TYPE OF TEST :
-
TD - Toxic dose (other than lowest)
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
SPECIES OBSERVED :
-
Rodent - mouse
-
DOSE/DURATION :
-
1275 mg/kg/34W-I
-
TOXIC EFFECTS :
-
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Liver - tumors Blood - leukemia
-
TYPE OF TEST :
-
TD - Toxic dose (other than lowest)
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
SPECIES OBSERVED :
-
Rodent - rat
-
DOSE/DURATION :
-
1300 mg/kg/1Y-I
-
TOXIC EFFECTS :
-
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Liver - tumors Blood - lymphoma, including Hodgkin's disease
-
TYPE OF TEST :
-
TD - Toxic dose (other than lowest)
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
SPECIES OBSERVED :
-
Rodent - rat
-
DOSE/DURATION :
-
300 mg/kg/6W-I
-
TOXIC EFFECTS :
-
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Liver - tumors Blood - lymphoma, including Hodgkin's disease
-
TYPE OF TEST :
-
TD - Toxic dose (other than lowest)
-
ROUTE OF EXPOSURE :
-
Parenteral
-
SPECIES OBSERVED :
-
Rodent - rat
-
DOSE/DURATION :
-
620 mg/kg/31W-I
-
TOXIC EFFECTS :
-
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Liver - tumors
-
TYPE OF TEST :
-
TD - Toxic dose (other than lowest)
-
ROUTE OF EXPOSURE :
-
Unreported
-
SPECIES OBSERVED :
-
Rodent - rat
-
DOSE/DURATION :
-
700 mg/kg/4W-I
-
TOXIC EFFECTS :
-
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Liver - tumors
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Oral
-
DOSE :
-
150 mg/kg
-
SEX/DURATION :
-
female 7-9 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Intraperitoneal
-
DOSE :
-
40 mg/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Intraperitoneal
-
DOSE :
-
12500 ug/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - Central Nervous System
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Intraperitoneal
-
DOSE :
-
12500 ug/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Specific Developmental Abnormalities - body wall
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Intraperitoneal
-
DOSE :
-
30 mg/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Intraperitoneal
-
DOSE :
-
14 mg/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Specific Developmental Abnormalities - eye/ear
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
10 mg/kg
-
SEX/DURATION :
-
female 7 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Effects on Newborn - behavioral
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
50 mg/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
50 mg/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
50 mg/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Intravenous
-
DOSE :
-
50 mg/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Specific Developmental Abnormalities - Central Nervous System
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Intravenous
-
DOSE :
-
15 mg/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Parenteral
-
DOSE :
-
5 mg/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Parenteral
-
DOSE :
-
50 mg/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Parenteral
-
DOSE :
-
150 mg/kg
-
SEX/DURATION :
-
female 8-10 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Unreported
-
DOSE :
-
225 mg/kg
-
SEX/DURATION :
-
female 7-9 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Intrauterine
-
DOSE :
-
2500 ug/kg
-
SEX/DURATION :
-
female 6 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Intraperitoneal
-
DOSE :
-
100 mg/kg
-
SEX/DURATION :
-
female 6 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Fertility - other measures of fertility
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Intraperitoneal
-
DOSE :
-
66667 ug/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - body wall
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Intraperitoneal
-
DOSE :
-
66667 ug/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Intraperitoneal
-
DOSE :
-
1 gm/kg
-
SEX/DURATION :
-
female 8-12 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Intraperitoneal
-
DOSE :
-
100 mg/kg
-
SEX/DURATION :
-
female 7 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
25 mg/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
160 mg/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
45 mg/kg
-
SEX/DURATION :
-
female 6-14 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
45 mg/kg
-
SEX/DURATION :
-
female 6-14 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Effects on Embryo or Fetus - fetal death
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
150 mg/kg
-
SEX/DURATION :
-
female 1 day(s) pre-mating female 2-7 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - gastrointestinal system
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
150 mg/kg
-
SEX/DURATION :
-
female 1 day(s) pre-mating female 2-7 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Intravenous
-
DOSE :
-
100 mg/kg
-
SEX/DURATION :
-
female 10 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Specific Developmental Abnormalities - gastrointestinal system
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
40 mg/kg
-
SEX/DURATION :
-
female 11 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Maternal Effects - parturition
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
40 mg/kg
-
SEX/DURATION :
-
female 11 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - body wall
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
40 mg/kg
-
SEX/DURATION :
-
female 11 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Parenteral
-
DOSE :
-
33 mg/kg
-
SEX/DURATION :
-
female 11 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
20 ug/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
20 ug/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - homeostasis
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
130 ug/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
900 ug/kg
-
SEX/DURATION :
-
female 8 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
25 mg/kg
-
SEX/DURATION :
-
female 18 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
25 mg/kg
-
SEX/DURATION :
-
female 13 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - body wall
-
TYPE OF TEST :
-
TDLo - Lowest published toxic dose
-
ROUTE OF EXPOSURE :
-
Subcutaneous
-
DOSE :
-
50 mg/kg
-
SEX/DURATION :
-
female 13 day(s) after conception
-
TOXIC EFFECTS :
-
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - urogenital system
-
TYPE OF TEST :
-
Unscheduled DNA synthesis
-
TYPE OF TEST :
-
Cytogenetic analysis
MUTATION DATA
-
TYPE OF TEST :
-
Unscheduled DNA synthesis
-
TEST SYSTEM :
-
Rodent - hamster Liver
-
DOSE/DURATION :
-
100 umol/L
-
REFERENCE :
-
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 136,255,1984 *** REVIEWS *** IARC Cancer Review:Animal Sufficient Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 8,267,1975 IARC Cancer Review:Human No Adequate Data IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 8,267,1975 IARC Cancer Review:Group 2B IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,56,1987 TOXICOLOGY REVIEW ADTEAS Advances in Teratology. (New York, NY) V.1-5, 1966-72. Discontinued. Volume(issue)/page/year: 1,131,1966 TOXICOLOGY REVIEW CLPTAT Clinical Pharmacology and Therapeutics (St. Louis). (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1960- Volume(issue)/page/year: 5,480,1964 TOXICOLOGY REVIEW ARVPAX Annual Review of Pharmacology. (Palo Alto, CA) V.1-15, 1961-75. For publisher information, see ARPTDI. Volume(issue)/page/year: 5,447,1965 TOXICOLOGY REVIEW JOPDAB Journal of Pediatrics. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63141) V.1- 1932- Volume(issue)/page/year: 59,1,1961 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - M2160 No. of Facilities: 62 (estimated) No. of Industries: 3 No. of Occupations: 11 No. of Employees: 1759 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - M2160 No. of Facilities: 55 (estimated) No. of Industries: 1 No. of Occupations: 3 No. of Employees: 813 (estimated) No. of Female Employees: 623 (estimated)
|
